Dedicated to Research Since 1993
  •  

    info@genesismarketinsights.com

Global Duchenne Muscular Dystrophy Treatment Market by Therapeutic Approach (Molecular based Therapies, Steroid Therapy) by Treatment Type (Corticosteroids, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)) – Business Overview, Analysis and Industry Forecast 2017-2023

 Healthcare and Pharmaceuticals

Report Overview

Global Duchenne Muscular Dystrophy Treatment Market was valued at USD XX billion in the year 2017. Global Duchenne Muscular Dystrophy Treatment market is further estimated to grow at a CAGR of XX % from 2018 to reach USD XX billion by the year 2023.

In the Global Duchenne Muscular Dystrophy Treatment Market, by region Europe holds the highest market share in 2017 and is also market is considered as the fastest growing market in the forecasted period owing to their market demands. The major factors contributing to the higher market share is the higher prevalence of genetic disease across EU and better healthcare infrastructure.

Drivers:

            Rising Disease Burden of Duchenne Muscular Dystrophy (DMD)

Restraints:

            Changing government regulations and norms.

Opportunities:

            Increasing Awareness Campaigns for DMD

Challenges:

            Stringent Regulatory Framework with High Product Cost Burden

The segmentation is done on the basis of By Therapeutic Approach, By Treatment Type, by end users, and by region. On the basis of Therapeutic Approach, the Molecular-based Therapies is expected to hold the highest market share during the forecast period. The segmentation is done on the basis of Treatment Type, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) segment is expected to hold the highest market share during the forecast period.

Pfizer, Inc., Santhera Pharmaceuticals, Bristol-Myers Squibb, Marathon Pharmaceuticals, Fibrogen Inc, among others are some of the key players in the Global Duchenne Muscular Dystrophy Treatment market.

Key Benefits for Stakeholders

Duchenne Muscular Dystrophy Treatment Manufacturers

Raw material suppliers

Research and Consulting Organization

End-use industries

Investment research firms

By Therapeutic Approach

Molecular-based Therapies

Steroid Therapy

Others

By Treatment Type

Corticosteroids

Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)

Others

By End Users

Hospitals/Clinics

Ambulatory Centers

Others

By Region

North America

Europe

Asia-Pacific

RoW

Key Market Players

BioMarin

Bristol-Myers Squibb

Fibrogen Inc

Marathon Pharmaceuticals

Nobelpharma Co., Ltd

NS Pharma, Inc

Pfizer Inc.

PTC Therapeutics

Santhera Pharmaceuticals

Sarepta Therapeutics

 (A brief overview of 10 companies is also provided)

Research Methodology:

Genesis Market Insights follows in-depth Research Methodology focused on reducing deviation in the collected data. GMI offers the most precise evaluations and projection for the market numbers. GMI engages following Market Engineering techniques –

  1.      Raw Market Data is collected and compared with the Existing in-house Data on a broad front.
  2.      Both Bottom-Up and Top-Down approaches are analyzed for segmenting and estimating measurable aspects of the market.
  3.      To avoid bias, we filter the collected data collected from authenticated sources.
  4.      GMI has a well proven Statistical Modeling System for estimates and forecasts.
  5.      Further, the report findings are validated with the Industry Expert Panel on face to face or telephonic interviews.
  6.      Panelists are approached from Leading Enterprises across the value chain including manufacturers, suppliers, technology providers, domain experts and buyers so as to validate a thorough and balanced market overview.

Detailed customization is also available for you. Further, if the report listed above does not meet your key requirements. Our customized research report will analytically cover the required market information you need which will help you to plan your business decisions.

Table Of Content

1. Introduction

1.1 Market Vision

       1.1.1 Market Definition

       1.1.2 Market Scope

1.2 Limitations

1.3 Stakeholders

2. Research Methodology

2.1. Research Process

       2.1.1. Secondary Research

             2.1.1.1. Key Data from Secondary Research

       2.1.2. Primary Research

             2.1.2.1. Key Data from Primary Research

             2.1.2.2. Breakdowns of Primary Interviews

2.2. Market Size Estimation

       2.2.1. Bottom-Up Approach

       2.2.2. Top-Down Approach

       2.2.3. Annual Revenue Process

2.3. Data Triangulation 

2.4. Research Assumptions 

       2.4.1. Assumption

3. Executive Summary

4. Market Overview

4.1. Introduction

4.2. Drivers

4.3. Restraints

4.4. Opportunities

4.5. Challenges

4.6. Regulations

4.7. Supply Chain/Value Chain Analysis

4.8. Patent & Standards

5. Industry Trends

5.1. Introduction

5.2. Porter’s Five Forces Analysis

       5.2.1. Threat of New Entrants

       5.2.2. Threat of Substitutes

       5.2.3. Bargaining Power of Buyers

       5.2.4. Bargaining Power of Suppliers

       5.2.5. Intensity of Competitive Rivalry

6. Duchenne Muscular Dystrophy Treatment Market, By Therapeutic Approach

6.1 Molecular-based Therapies

6.2 Steroid Therapy

6.3 Others

7. Duchenne Muscular Dystrophy Treatment Market, By Treatment Type

7.1 Corticosteroids

7.2 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)

7.3 Others

8. Duchenne Muscular Dystrophy Treatment Market, End Users

8.1 Hospitals/Clinics

8.2 Ambulatory Centers

8.3 Others

9. Geographical Analysis

9.1. Introduction

9.2. North America

       9.2.1. U.S.

       9.2.2. Canada

       9.2.3. Mexico

9.3. Europe

       9.3.1. U.K.

       9.3.2. Germany

       9.3.3. France

       9.3.4. RoE

9.4. Asia Pacific

       9.4.1. South Korea

       9.4.2. China

       9.4.3. Japan

       9.4.4. RoAPAC

9.5. RoW

       9.5.1. Latin America

       9.5.2. Middle East and Africa

10. Company Profiles

(Business Overview, Financial Overview, Product write Up, Recent Developments)

10.1 BioMarin

10.2 Bristol-Myers Squibb

10.3 Fibrogen Inc

10.4 Marathon Pharmaceuticals

10.5 Nobelpharma Co., Ltd

10.6 NS Pharma, Inc

10.7 Pfizer Inc.

10.8 PTC Therapeutics

10.9 Santhera Pharmaceuticals

10.10 Sarepta Therapeutics

(A brief overview of 10 companies is also provided.)

11. Competitive Analysis

11.1. Introduction

11.2. Market Positioning of Key Players

11.3 Competitive Strategies Adopted by Leading Players

        11.3.1. Investments & Expansions

        11.3.2. New Product Launches

        11.3.3. Mergers & Acquisitions

        11.3.4. Agreements, Joint Ventures, and Partnerships

12. Appendix

12.1. Questionnaire

12.2. Available Customizations 

12.3. Upcoming Events (Trade Fair, Exhibitions, Conferences)

* The list of tables and figures will be provided in the sample report.

Summary

No Content Available.

PURCHASE OPTIONS

ASK FOR SPECIAL PRICING

Related Reports